Part,  Chapter, Paragraph

  1    I,     2. 10.  4(12)|    Westmenister Healthcare NHS Trust, K. Robertson Ref. “Coding
  2    I,     3.  4        |               E, Liefbroer A, Henkens K (2001): De timing van het
  3    I,     3.  4        |                Esveldt, I., G. Beets, K. Henkens, A. Liefbroer &
  4   II,     4.  3        |     References~ ~Anderson R, Kochanek K, et al. (1997): Report of
  5   II,     5.  2.  7    |           1588-1592.~Daviglus ML, Liu K, Pirzada A, Yan LL, Garside
  6   II,     5.  2.  7    |         Ferrario M, Sans S, Kuulasmaa K, for the WHO MONICA Project (
  7   II,     5.  2.  7    |              J 27: 107-113.~Kuulasmaa K, Tunstall-Pedoe H, Dobson
  8   II,     5.  2.  7    |                London.~Pisa Z, Uemura K (1982): Trends of mortality
  9   II,     5.  2.  7    |              M, Tuomilehto J, Asplund K, for the WHO MONICA Project (
 10   II,     5.  2.  7    |         Tolonen H, Mahonen M, Asplund K, rastenyte D, Kuulasma K,
 11   II,     5.  2.  7    |              K, rastenyte D, Kuulasma K, Vanuzzo D, Tuomilehto J
 12   II,     5.  2.  7    |           Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski
 13   II,     5.  2.  7    |             Lancet 355:688-700~Uemura K, Pisa Z (1988): Trends in
 14   II,     5.  4.  8    |              271-6~Beck, P, Battlogg, K, Gfrerer, R, Trajanoski,
 15   II,     5.  4.  8    |              Ottosen P, Borch-Johnsen K (2008); on behalf of the
 16   II,     5.  5.Int(18)|                      Makino M, Tsuboi K, Dennerstein L.(2004): Prevalence
 17   II,     5.  5.  1    |        Kessler R, Nelson C, McGonagle K, Liu G (1996): Comorbidity
 18   II,     5.  5.  1    |            330-41.~ ~Värnik A, Kölves K, van der Feltz-Cornelius
 19   II,     5.  5.  3    |                 Berkman, N. D.; Lohr, K. N.; Bulik, C. M. (2007):
 20   II,     5.  5.  3    |        Gilbert CC, Bergman P, Widhalm K, Manios Y, Breidenasse C,
 21   II,     5.  5.  3    |                No. 4, 351-357.~Harper K, Sperry S, Thompson JK (
 22   II,     5.  5.  3    |           Misra M, Aggarwal A Miller, K.K, Almazan, C, Worley, M,.
 23   II,     5.  5.  3    |               M, Aggarwal A Miller, K.K, Almazan, C, Worley, M,.
 24   II,     5.  5.  3    |             77.~Andrews G, Sandersson K, Corry J, Issakidis C, Lapsley
 25   II,     5.  5.  3    |               46:549-55.~Demyttenaere K, Bruffaerts R, Posada-Villa
 26   II,     5.  5.  3    |              BM, Isacson D, Bingefors K, Widerlöv B (2007): Mortality
 27   II,     5.  5.  3    |               33.~Häfner H and Maurer K (2006): Early detection
 28   II,     5.  5.  3    |               130-8.~Häfner H, Maurer K, Ruhrmann S, Bechdolf A,
 29   II,     5.  5.  3    |        Stiegler M, Rummel C, Wahlbeck K, Kissling W (2006): Call
 30   II,     5.  5.  3    |          Tuori T, Gissler M, Wahlbeck K), Section B, p. 257-333,
 31   II,     5.  5.  3    |              Court et al., 1996 (*)~U.K. ~All ages ~GP files~? ~
 32   II,     5.  5.  3    |               Pond et al., 1960 (*)~U.K. ~Children 4-20 years ~MR
 33   II,     5.  5.  3    |              a study made in Wales, U.K., a strong independent correlation
 34   II,     5.  5.  3    |               6~Nilsson et al, 1997~U.K.~GP/MF~Incident cohort~149~
 35   II,     5.  5.  3    |              13.~Gaitatzis A, Carroll K, Majeed A, Sander JW (2004):
 36   II,     5.  5.  3    |        Psychiatry 32:115-122.~Bencsik K, Rajda C, Füvesi J, et al (
 37   II,     5.  5.  3    |                In: Firnhaber W, Lauer K (eds): Multiple Sclerosis
 38   II,     5.  5.  3    |           Koch-Henriksen N, Hyllested K (1994): Survival of patients
 39   II,     5.  5.  3    |               389.~Firnhaber W, Lauer K (eds) (1994): Multiple Sclerosis
 40   II,     5.  5.  3    |            265.~Fox-Rushby JA, Hanson K (2001): Calculating and
 41   II,     5.  5.  3    |              Neurol 53:793-798.~Gross K, Kokk A, Kaasik AE (1993):
 42   II,     5.  5.  3    |           Koch-Henriksen N, Hyllested K (1988): Epidemiology of
 43   II,     5.  5.  3    |           Brønnum-Hansen H, Hyllested K (1992): Incidence of multiple
 44   II,     5.  5.  3    |                In: Firnhaber W, Lauer K (eds): Multiple Sclerosis
 45   II,     5.  5.  3    |                In: Firnhaber W, Lauer K (eds): Multiple Sclerosis
 46   II,     5.  5.  3    |        Milanov I, Georgiev D, Kmetska K, Jordanova L, Topalov N (
 47   II,     5.  5.  3    |                In: Firnhaber W, Lauer K (eds): Multiple Sclerosis
 48   II,     5.  5.  3    |            575-585.~Prange AJA, Lauer K, Poser S et al (1986): Epidemiological
 49   II,     5.  5.  3    |          Larsen JP, Tandberg E, Laake K (2000): Predictors of nursing
 50   II,     5.  5.  3    |             KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM,
 51   II,     5.  5.  3    |            Lai BC, Marion SA, Teschke K, Tsui JK (2002): Occupational
 52   II,     5.  5.  3    |            von Campenhausen S, Berger K, Koehne-Volland R, Rieke
 53   II,     5.  5.  3    |          Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel
 54   II,     5.  5.  3    |           Oertel W, Siebert U, Berger K, Dodel R (2005): Prevalence
 55   II,     5.  5.  3    |            473-490.~Whetten-Goldstein K, Sloan F, Kulas E, Cutson
 56   II,     5.  6.  6    |               G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald
 57   II,     5.  6.  6    |              S, Herrstrom P, Hogstrom K, Petersson IF, Svensson
 58   II,     5.  6.  6    |              JM, Klareskog L, Machold K, Martin-Mola E, Nielsen
 59   II,     5.  6.  6    |          Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley
 60   II,     5.  6.  6    |               Lock C, Allgar V, Jones K, Marples G, Chandler C,
 61   II,     5.  6.  6    |               1141~Merx H, Dreinhofer K, Schrader P, Sturmer T,
 62   II,     5.  6.  6    |              555-558~Palmer KT, Walsh K, Bendall H, Cooper C, Coggon
 63   II,     5.  6.  6    |           Elsevier,~Woolf AD, Akesson K (2003): Preventing fractures
 64   II,     5.  6.  6    |               56~Woolf AD and Akesson K (2006): The Patient with
 65   II,     5.  7.  7    |            432-44.~Baigent C, Burbury K, Wheeler D (2000): Premature
 66   II,     5.  7.  7    |               JW, Spruill M, Reynolds K, et al (2005) Prevalence
 67   II,     5.  7.  7    |              2275-84.~Hallan SI, Dahl K, Oien CM, Grootendorst DC,
 68   II,     5.  7.  7    |           National Kidney Foundation. K/D The seventh report of
 69   II,     5.  7.  7    |           National Kidney Foundation. K/DOQI clinical practice guidelines
 70   II,     5.  7.  7    |           National Kidney Foundation. K/DOQI clinical practice guidelines
 71   II,     5.  7.  7    |           National Kidney Foundation. K/DOQI clinical practice guidelines
 72   II,     5.  7.  7    |           National Kidney Foundation. K/DOQI clinical practice guidelines
 73   II,     5.  7.  7    |          Jager KJ, Dekker FW, Simpson K, et al (2003): Trends in
 74   II,     5.  8.  7    |              P, Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz
 75   II,     5.  8.  7    |           Milton D, Schwartz D, Toren K, Viegi G (2003): American
 76   II,     5.  8.  7    |              797~ ~Bergdahl IA, Toren K, Eriksson K, Hedlund U,
 77   II,     5.  8.  7    |        Bergdahl IA, Toren K, Eriksson K, Hedlund U, Nilsson T, Flodin
 78   II,     5.  8.  7    |       Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia
 79   II,     5.  8.  7    |              123: 1684-1692.~ ~Horton K (2008): The use of telecare
 80   II,     5.  8.  7    |               S, Sandstrom T, Larsson K (2003): Obstructive Lung
 81   II,     5.  8.  7    |              Radon R, Jarvis D, Toren K, Künzli N, Norbäck D, d'
 82   II,     5.  9.  7    |        Compalati E, Penagos M, Henley K, Canonica GW (2007): Allergy
 83   II,     5.  9.  7    |          Custis N, Ronmark E, Wickens K, Sporik R, Woodfolk JA,
 84   II,     5.  9.  7    |         Gehring U, , Jacob B, Richter K, Fahlbusch B, Schlenvoigt
 85   II,     5.  9.  7    |            108(1 Suppl):S2-8.~ ~Torén K (2004): A prospective study
 86   II,     5. 10.  7    |               Ballmer-Weber BK, Beyer K, Conti A, Dubakiene R, Fernandez-Rivas
 87   II,     5. 10.  7    |              M, Hoffmann-Sommergruber K, Lidholm J, Mustakov T,
 88   II,     5. 10.  7    |            Mackie AR, Burney P, Beyer K, Frewer L, Madsen C, Botjes
 89   II,     5. 10.  7    | Sigurdardottir S, Lindner T, Goldhahn K, Dahlstrom J (2007): The
 90   II,     5. 10.  7    |      foodallergens.ifr.ac.uk~ ~Thomas K, Herouet-Guicheney C, Ladics
 91   II,     5. 11.  3    |              25% in 1999 (C Lidén and K Norberg, 2005). In a study
 92   II,     5. 11.  3    |               IM Freedberg, AZ Eisen, K Wolff, KF Austen, LA Goldsmith,
 93   II,     5. 11.  3    |           Hasan T, Rantanen T, Alanko K, Harvima RJ, Jolanki R,
 94   II,     5. 11.  3    |         Harvima RJ, Jolanki R, Kalimo K, Lahti A, Lammintausta K,
 95   II,     5. 11.  3    |              K, Lahti A, Lammintausta K, Lauerma AI, Laukkanen A,
 96   II,     5. 11.  3    |      luukkaala T, Riekki R, Turjanmaa K, Varjonen E, Vuorela AM,
 97   II,     5. 11.  3    |                2001:935950.~C Lidén, K Norberg, Nickel on the Swedish
 98   II,     5. 11.  7    |           2001;81:268272.~ ~Weismann K, Krakauer R, Wanscher B (
 99   II,     5. 12.  7    |         Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G,
100   II,     5. 15.  6    |              Jul 7.~McCabe C, Claxton K, Tsuchiya A (2005): Orphan
101   II,     7.  7        |          Organization, Peden M, McGee K, Sharma G.~ ~Racioppi F,
102   II,     8.  2.  1    |         Research 51, 866-874.~Fisher, K., (2004). Health Disparities
103   II,     8.  2.  1    |              2008~Mason, J., & Scior, K., (2004). Diagnostic overshadowing
104   II,     8.  2.  1    |           Luckasson, R.A. and Shogren K.A., With Borthwick-Duffy,
105   II,     8.  2.  3    |              13~ ~Uimonen S, Huttunen K, Jounio-Ervasti K, Sorri
106   II,     8.  2.  3    |            Huttunen K, Jounio-Ervasti K, Sorri M (1999): Do we know
107   II,     9.  1.  1    |               CV, Joseph KS, Demissie K, Vintzileos AM (2005): Trends
108   II,     9.  1.  1    |                  Alexander S, Wildman K, Zhang W, Langer M, Vutuc
109   II,     9.  1.  1    |              192.~Kramer MS, Demissie K, Yang H, Platt RW, Sauve
110   II,     9.  1.  1    |             63.~ ~Kramer MS, Demissie K, Yang H, Platt RW, Sauve
111   II,     9.  1.  1    |           Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR (
112   II,     9.  1.  1    |             103.~ ~Zeitlin J, Wildman K, Breart G, Alexander S,
113   II,     9.  1.  2    |            Vol 82, pp 349-352.~Waller K, Shaw GM, Rasmussen SA et
114   II,     9.  2.  7    |             asp?intId=29].~ ~Matharu, K., Ozanne, S (2004): The
115   II,     9.  2.  7    |           Ollila E, Lahtinen E, Leppo K (eds.) (2006): Health in
116   II,     9.  3.  1    |                  Brownhill S, Wilhelm K, Barclay L & Schmied V (
117   II,     9.  3.  1    |              accessed 07.07)~ ~Fenton K A and Lowndes C M (2004):
118   II,     9.  3.  1    |               973-6~ ~Lee H, McGovern K, Finkelstein JS & Smith
119   II,     9.  3.  1    |            1516-23~ ~Makino M, Tsuboi K, Dennerstein L (2004); Prevalence
120   II,     9.  3.  1    |                3-6.~ ~White AK , Cash K (2003): The state of men’
121   II,     9.  3.  2    |                  Alexander S, Wildman K, Zhang W, Langer M, Vutuc
122   II,     9.  3.  2    |               CV, Joseph KS, Demissie K, Vintzileos AM (2005): Trends
123   II,     9.  3.  2    |            192.~ ~Kramer MS, Demissie K, Yang H, Platt RW, Sauve
124   II,     9.  3.  2    |           Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR (
125   II,     9.  3.  2    |             103.~ ~Zeitlin J, Wildman K, Breart G, Alexander S,
126   II,     9.  3.  3    |               AM, Le Pont F, Wellings K, Spira A, Field J. (1995):
127   II,     9.  3.  3    |           Hamers FF, Infuso A, Fenton K (2004) : Monitoring HIV/AIDS
128   II,     9.  3.  3    |          Finland.~Herlitz C, Ramstedt K (2005): Assessment of sexual
129   II,     9.  3.  3    |                Rodrigues LC, Wellings K, Weiss HA, Hayes R (2005):
130   II,     9.  3.  3    |               McGee H, Qual A, Rundle K, Cousins G, Donnelly C,
131   II,     9.  3.  3    |               1998 and 2003.~Wellings K, Nanchahak K, Macdowall
132   II,     9.  3.  3    |           2003.~Wellings K, Nanchahak K, Macdowall W, McManus S,
133   II,     9.  3.  3    |            9296): 1843-1850.~Wellings K, Collumbien M, Slaymaker
134   II,     9.  4.  7    |                Alaszewski A.M., Coxon K.; Summary (2004): Towards
135   II,     9.  5.  6    |       caregiving. (Edited by: Willson K). Aurora, Ontario: Garamond
136   II,     9.  5.  6    |               28.~ ~Risberg G, Hamber K, Johansson E (2006): Gender
137   II,     9.  5.  6    |              accessed 07.07)~ ~Stiehr K (2004): MERI: Mapping existing
138  III,    10.  1.  3    |            Bull 114(2):376-90.~Melzer K, Kayser B, Saris WHM, Pichard
139  III,    10.  2.  1    |             pdf~ ~Bates C, Fagerström K, Jarvis MJ, Kunze M, McNeill
140  III,    10.  2.  1    |              1207.~ ~Kunst AE, Giskes K, Mackenbach JP. Socioeconomic
141  III,    10.  2.  1    |                Luo J, Ye W, Zendehdel K, Adami J, Adami H-O, Bofetta
142  III,    10.  2.  1    |                Bohadana A, Fagerström K (2007): Introducing oral
143  III,    10.  2.  1    |               G, Giesbrecht N, Graham K, Grube JW, Gruenewald PJ,
144  III,    10.  2.  1    |            Stokes E, Sumnall H, Witty K, Bellis M (2007): A review
145  III,    10.  2.  1    |              49(3):131-133.~ ~Maxwell K, Tucker L (1992): Effects
146  III,    10.  2.  1    |             865.~ ~Popkin B M, Duffey K, Gordon-Larsen P (2005):
147  III,    10.  2.  1    |              Information.~ ~Bayingana K, Demarest S, Gisle L, Hesse
148  III,    10.  2.  1    |                   Bromley C, Sproston K, Shelton N, eds (2005a):
149  III,    10.  2.  1    |                   Bromley C, Sproston K, Shelton N, eds (2005b):
150  III,    10.  2.  1    |         Rolland-Cachera MF, Castetbon K, Arnault N, Bellisle F,
151  III,    10.  2.  1    |               Oltarzewski M, Figurska K.): Warsaw, Prace IŻŻ 101;
152  III,    10.  2.  1    |           Nutr. 4: 537-545.~ ~Kraemer K, Zimmermann MB (ed.). Nutritional
153  III,    10.  2.  1    |          Spencer E, Stripp C, Overvad K, Clavel-Chapelon F, Casagrande
154  III,    10.  2.  1    |      McTaggart A, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon
155  III,    10.  2.  1    |        McTaggart A, Allen NE, Overvad K, Tjonneland A, Clavel-Chapelon
156  III,    10.  2.  1    |          Welch A, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon
157  III,    10.  2.  1    |            Miller AB, Schulz M, Botsi K, Naska A, Sieri S, Sacerdote
158  III,    10.  2.  1    |               AA, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon
159  III,    10.  2.  1    |         Miller AB, Klipstein-Grobusch K, Lagiou P, Kalapothaki V,
160  III,    10.  2.  1    |      McTaggart A, Spencer EA, Overvad K, Tjonneland A, Stripp C,
161  III,    10.  2.  1    |          Boeing H, Klipstein-Grobusch K, Trichopoulou A, Vasilopoulou
162  III,    10.  2.  1    |           Kesse E, Klipstein-Grobusch K, San-Jose B, Welch AA, Krogh
163  III,    10.  2.  1    |             Luben R, Allen N, Overvad K, Tjonneland A, Clavel-Chapelon
164  III,    10.  2.  1    |          Luben R, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon
165  III,    10.  2.  1    |       Linseisen J, Klipstein-Grobusch K, Benetou V, Zavitsanos X,
166  III,    10.  2.  4    |                61:466-471.~ ~Hoffmann K., Mattheisen M, Dahm S,
167  III,    10.  2.  4    |           1251.~ ~Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo
168  III,    10.  2.  4    |          Warden DR, Smith D, Sleegens K, Prince JA, van Duijn CM,
169  III,    10.  2.  4    |    Gómez-Barbero M, Stein A J, Bock A K (2007): Consequences, Opportunities
170  III,    10.  2.  5    |               50.~ ~Mäntymaa M, Puura K, Luoma I, Salmelin R, Davis
171  III,    10.  2.  5    |            2003;29(3):181-91.~ ~Puura K, Davis H, Papadopoulou K,
172  III,    10.  2.  5    |              K, Davis H, Papadopoulou K, Tsiantis J, Ispanovic-Radojkovic
173  III,    10.  2.  5    |         Available at http ~ ~Wahlbeck K, Forsen T, Osmond C, Barker
174  III,    10.  3.  1    |            Stockholm, Sweden.~Leuraud K, Billon S, Bergot D, Tirmarche
175  III,    10.  3.  2    |             296: 199-208.~ ~Ravindra, K, L Bencs, R van Grieken (
176  III,    10.  4.  2    |           Available at: htt ~ ~Inoue, K, Okada, F, Ito, R, Kato,
177  III,    10.  5.  1    |                Walinder R, Gunnarsson K, Runeson R, Smedje G (2007)
178   IV,    11.  6.  5    |               Research into Practice. K. Walshe and R. Boaden. Berkshire,
179   IV,    11.  6.  5    |               Fund.~ ~Goldman M, Wood K (2007): European research
180   IV,    11.  6.  5    |         Political Science.~ ~Hinrichs K (1997): Social Insurances
181   IV,    11.  6.  5    |               Research into Practice. K. Walshe and R. Boaden. Berkshire,
182   IV,    11.  6.  5    |               Organization.~ ~McGrail K, Green B et al. (2000): "
183   IV,    11.  6.  5    |               1601.~ ~Naylor CD, Iron K et al. (2002): Measuring
184   IV,    11.  6.  5    |    Pharmacotherapy 26: 422-8.~ ~Taxis K, Barber N (2003): "Ethnographic
185   IV,    11.  6.  5    |     Communities.~ ~van de Ven W, Beck K et al. (2003). "Risk adjustment